Related Experiment Video
Updated: Oct 18, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Physical Growth of Patients with Hereditary Tyrosinaemia Type I: A Single-Centre Retrospective Study
Ozlem Yilmaz1,2,3, Anne Daly1, Alex Pinto1
1Birmingham Women's and Children's Hospital, Birmingham B4 6NH, UK.
Insights
Hereditary tyrosinaemia type I (HTI) patients showed improved growth over time, with height, weight, and BMI z-scores increasing with age. Protein intake positively impacted height growth in this cohort.
Area of Science:
- Pediatrics
- Metabolic Disorders
- Genetics
Background:
- Hereditary tyrosinaemia type I (HTI) is a rare genetic disorder affecting amino acid metabolism.
- Long-term growth patterns in HTI patients require further investigation.
Purpose of the Study:
- To assess long-term growth outcomes in patients with hereditary tyrosinaemia type I.
- To identify factors influencing growth in HTI patients.
Main Methods:
- Retrospective review of 17 HTI patients.
- Analysis of height, weight, and BMI z-scores over time.
- Correlation of growth with protein intake.
Main Results:
- HTI patients exhibited improved height, weight, and BMI z-scores with age, approaching normal population standards.
- Overweight and obesity prevalence increased from <5 years to 7-16 years.
- Higher prescribed total protein intake was linked to better height growth (p < 0.01).
Conclusions:
- Growth impairment in early life can improve with age in HTI patients.
- Protein intake is a significant factor in height development.
- Further research is needed to fully understand growth determinants in HTI.
Abstract:
In a retrospective review, we aimed to assess long-term growth in 17 patients (n = 11 males) with hereditary tyrosinaemia type I (HTI). Median age at assessment was 15.6 years (5.7-26.6 years) and median age at diagnosis was 1 month (range: 0-16 months), with 35% (n = 6/17) symptomatic on presentation. From the age of 8 years, there was a noticeable change in median height, weight, and body-mass-index [BMI]-z-scores. Median height-for-age z-scores were consistently ≤ -1 (IQR -1.6, -0.5) during the first 8 years of life but increased with age. Weight-for-age z-scores ranged between -1 to 0 (IQR -1.2, 0.1) in the first 8 years; then increased to > 0.5 (IQR -0.3, 1.3) by age 16 years, and BMI-for-age z-scores ranged from 0 to 1 (IQR -0.7, 1.3) up to 8 years, and >1 (IQR -0.2, 1.9) until 16 years. The percentage of overweight and obesity was lowest in children aged < 5 years, and consistently > 40% in patients aged between 7 to 16 years. The prescribed total protein intake was associated with improved height growth (p < 0.01). Impaired growth in early life improved with age achieving normal population standards. Further studies are needed to investigate factors that influence growth outcome in HTI patients.
More Related Videos
Related Concept Videos
Inborn Errors of Metabolism
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pedigree Analysis
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Heritability

